<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108285</url>
  </required_header>
  <id_info>
    <org_study_id>9009/21</org_study_id>
    <nct_id>NCT05108285</nct_id>
  </id_info>
  <brief_title>Dark Halo and MNV: a Study Between ICGA and OCTA</brief_title>
  <official_title>Dark Halo a New Biomarker in Macular Neovascularization: a Comparative Study Between ICGA and OCTA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of study is to compare the evaluation of dark halo area of macular neovascularization&#xD;
      (MNV) between indocyanine green angiography (ICGA) and optical coherence tomography&#xD;
      angiography (OCTA) in order to identify OCTA as effective and useful biomarker in MNV&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dark halo is defined as a dark perilesional of flow decrease due to an area of reduced&#xD;
      choroidal flow adjacent to the macular neovascularization (MNV).&#xD;
&#xD;
      The detection of MNV vascular details was only possible through invasive dye injection, such&#xD;
      as fluorescein angiography (FA) or indocyanine green angiography (ICGA).&#xD;
&#xD;
      Optical coherence tomography angiography (OCTA) is a recent imaging technique that is able to&#xD;
      detect the perfusion and non-perfusion areas carefully.&#xD;
&#xD;
      The aim of study is to compare the evaluation of dark halo area of MNV between ICGA and OCTA&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dark halo measurement</measure>
    <time_frame>three years</time_frame>
    <description>The OCTA and ICGA parameters analyzed are: the area of dark halo (mm2) that surrounds the coroidal neovascularization.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Macular Neovascularisation</condition>
  <arm_group>
    <arm_group_label>MNV group</arm_group_label>
    <description>Eyes affected by MNV. The dark halo of MNV was evaluated by OCTA and ICGA</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Coherence Tomography Angiography (OCTA) and indocyanine green angiography (ICGA)</intervention_name>
    <description>OCTA and ICGA is able to detect the dark halo as a area of reduced perfusion around MVN</description>
    <arm_group_label>MNV group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A group of patients affected by MNV is subjected to OCTA and ICGA analysis in order to&#xD;
        evaluate which of two methods is able to detect in a peculiar way the dark halo around the&#xD;
        MNV&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age older than 55 years&#xD;
&#xD;
          -  diagnosis of macular neovascularization&#xD;
&#xD;
          -  absence of previous treatment with anti-Vegf injections&#xD;
&#xD;
          -  absence of other retinal vascular diseases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age younger than 55 years&#xD;
&#xD;
          -  absence diagnosis of macular neovascularization&#xD;
&#xD;
          -  presence of previous treatment with anti-Vegf injections&#xD;
&#xD;
          -  presence of other retinal vascular diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilda Cennamo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universit√† Federico II</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Naples &quot;Federico II&quot;</name>
      <address>
        <city>Naples</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Gilda Cennamo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

